Cortagen

Cortagen is a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid, and proline (Ala-Glu-Asp-Pro, single-letter code AEDP). Molecular weight is 430.4 g/mol. It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology. The compound was identified by epitope mapping as a principal active component within Cortexin, the polyclonal brain cortex extract that has the longest Russian clinical use among CNS-targeted bioregulators.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures of peptides up to several kDa. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. For the brain cortex, Cortexin is the Cytomax and Cortagen is the Cytogen. The standard Russian sequence is initial-phase Cytogen treatment followed by extended-support Cytomax administration.

The AEDP tetrapeptide differs by a single C-terminal residue from Epitalon (AEDG, pineal Cytogen): proline vs glycine. This is a recurring pattern in the Khavinson Cytogen family, where single-residue C-terminal differences are claimed to redirect organ targeting from one tissue to another. The plausibility of strict tissue specificity from single-residue changes is debatable on structural grounds, and the issue has been raised in independent reviews of the bioregulator framework.

The Evidence

The compound-specific evidence base consists of:

Gene expression work (Anisimov, Khavinson, and Anisimov, 2004). Microarray analysis after Cortagen administration in mouse heart documented changes across 110 genes spanning 234 DNA regions, including stress-response genes (Pass1, Hsc70) and developmental signals (Bmp2, Wnt4). The off-target heart effects from a peptide claimed to be cortex-specific raise legitimate questions about tissue selectivity claims.

Nerve regeneration (Turchaninova et al., 2000). Animal studies of sciatic nerve transection reported faster nerve regeneration in Cortagen-treated rats compared with controls. Magnitude estimates approximately 30 to 40 percent faster nerve regrowth.

Ischemic brain injury models. Russian preclinical work has documented reduced infarct size and improved behavioral recovery in rodent stroke models after Cortagen administration.

Chromatin and gene expression mechanism work has continued through the broader Khavinson program, with the proposed mechanism of nuclear peptide-DNA interaction extending to AEDP.

Independent Western confirmation is sparse. PubMed indexing returns predominantly Khavinson-affiliated publications. No registered ClinicalTrials.gov trial exists for Cortagen specifically as of May 2026.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Sold as a biologically active dietary supplement.

WADA. Not on 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation framework.

Cellular entry and nuclear binding. AEDP is hypothesized to enter neurons and other cells, reach the nucleus, and bind DNA in specific promoter regions. The Khavinson model treats this as the basis for tissue-selective gene-expression modulation, though the specific DNA target sequences for AEDP have not been comprehensively mapped.

Chromatin effects. Lezhava and colleagues, 2015 reported epigenetic regulation of "aged" heterochromatin by Cortagen, with decondensation of pericentromeric heterochromatin in cells from elderly donors. The effect parallels findings reported with Livagen and other Khavinson Cytogens, suggesting a shared mechanism class rather than tissue-specific molecular targeting.

Downstream effects. Cortagen administration in animal models has been associated with:

• Modulation of stress-response gene expression
• Effects on inflammatory cytokine markers in CNS tissue
• Possible neurotrophic factor modulation
• Anti-oxidant effects in neural tissue homogenates
• Acceleration of peripheral nerve regeneration

The proline C-terminus is reported to confer modest carboxypeptidase resistance compared with peptides ending in less-hindered residues, though this does not fundamentally alter the rapid plasma clearance expected for an unmodified tetrapeptide.

Pharmacokinetics. No published human pharmacokinetic data on plasma half-life, tissue distribution, oral bioavailability, or blood-brain barrier penetration exists for Cortagen. The Khavinson framework proposes signaling at the gut-mucosa interface for oral administration, propagated systemically through neural and humoral pathways.

Animal model and Russian observational data report:

• Acceleration of peripheral nerve regeneration after transection injury
• Reduction in infarct size and behavioral deficits in rodent ischemic stroke models
• Anti-inflammatory effects in CNS tissue under various stressors
• Modulation of oxidative stress markers in neural homogenates
• Modulation of immune function markers in some models
• Use as adjunct in post-stroke rehabilitation in Russian protocols

Research-chemical user reports describe subjective cognitive improvements, focus enhancement, and possible benefits in recovery from concussion or mild traumatic brain injury. User reports are anecdotal, uncontrolled, and not verified for vial identity.

None of these effects has been quantified in a Western-standard placebo-controlled trial.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Cortagen.

The Russian retail Cortagen is dosed as 1 to 2 capsules once or twice daily before meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 20 mg of active peptide.

Research-chemical Cortagen is sold as lyophilized powder in 20 mg vials. Subcutaneous protocols in research-chemical communities typically use 100 to 500 mcg per day over 10 to 20 day cycles. These doses are extrapolated from rodent body-surface-area scaling and informal community experience; they lack Cortagen-specific human pharmacokinetic support.

The microarray study by Anisimov and colleagues used a 5-day injection schedule in mice but did not establish a clinical dose range that translates to humans. No dose-response studies have been published in any species.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation for Cortagen lists individual intolerance, pregnancy, and lactation as contraindications. No serious adverse events have been reported in Russian-language publications.

The constituent amino acids (alanine, glutamic acid, aspartic acid, proline) are common dietary amino acids. Tetrapeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure.

Long-term human safety data with controlled endpoints does not exist. Theoretical concerns specific to chronic neural gene-expression modulation:

• Effects on seizure threshold with chronic neuroactive peptide use are uncharacterized
• Drug-drug interactions with cholinesterase inhibitors, NMDA antagonists, SSRIs, and other CNS-active medications have not been studied
• Effects in patients with active neurological disease (multiple sclerosis, Parkinson's, epilepsy) have not been evaluated
• The off-target effects on cardiac and immune gene expression demonstrated in the 2004 microarray study suggest broader systemic effects than the cortex-specific marketing positioning implies

No carcinogenicity assessment has been published for Cortagen specifically. While related Khavinson peptides have been reported to show anti-tumor effects, the broad gene-regulatory activity warrants chronic-use caution that has not been formally addressed.

Within the Khavinson system, Cortagen is the synthetic Cytogen for the brain cortex axis. The standard sequence pairs Cortagen with Cortexin as the extended-support Cytomax.

For broader CNS bioregulator stacks, Cortagen combines with:

• Pinealon (EDR tripeptide for general neural and pineal-axis support)
• Cerluten (brain Cytomax for broader CNS coverage)
• Epitalon (AEDG pineal Cytogen for longevity and circadian effects)
• Semax and Selank (better-characterized Russian nootropic heptapeptides) for combined approaches

No combined-stack human trial has been published. The combinations rest on the broader Khavinson framework rather than on compound-specific clinical evidence.

External comparators in CNS pharmacology have substantial Phase 3 evidence bases:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for symptomatic Alzheimer's disease treatment
• Memantine for moderate-to-severe Alzheimer's disease
• Amyloid-targeting antibodies (lecanemab, donanemab) for early symptomatic Alzheimer's disease
• Stroke rehabilitation interventions (physical therapy, occupational therapy, speech therapy) with established efficacy

Cortagen has no comparable evidence base and is not a substitute for these established approaches in clinically significant CNS disease. Its role, if any, is as an investigational supplement in research contexts.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.